MedElevator
Войти в исследования Pediatric blood & cancer · 2026
Increased Risk of Sarcomas in Children With Congenital Anomalies: Findings From the Genetic Overlap Between Anomalies and Cancer in Kids (GOBACK) Registry Linkage Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wolters Russ, Tark Ji Yun, Chambers Tiffany M, Desrosiers Tania A, Scheurer Michael E, Shumate Charles, Nembhard Wendy N, Yazdy Mahsa M, Nestoridi Eirini, Janitz Amanda E, Tanner Jean Paul, Kirby Russell S, Salemi Jason L, Yu Yao, Huff Chad D, Plon Sharon E, Lupo Philip J, Schraw Jeremy M
Аннотация
BACKGROUND: Pediatric sarcomas are a heterogeneous group of tumors that contribute disproportionately to cancer mortality in children. Although congenital anomalies are among the strongest known risk factors for childhood cancer, the risk of specific sarcoma subtypes among affected individuals has not yet been thoroughly evaluated.
PROCEDURE: We obtained data on maternal and perinatal characteristics, congenital anomalies, and pediatric sarcoma diagnoses for all live births in nine states. We used Cox proportional hazards regression to estimate the hazard ratio (HR) and 95% confidence interval (CI) of sarcoma (overall and by subtype) among children with non-syndromic congenital anomalies. We considered all non-syndromic anomalies collectively, and when sample size allowed, we also evaluated specific anomaly-sarcoma associations.
RESULTS: We evaluated 21,933,884 children, including 641,770 (2.9%) with major non-syndromic congenital anomalies. Compared to children without a congenital anomaly, children with a non-syndromic anomaly had a two-fold higher hazard for any soft tissue sarcoma (95% CI: 1.7-2.5), including rhabdomyosarcoma (HR 2.2, 95% CI: 1.7-3.0) and embryonal rhabdomyosarcoma (HR 2.5, 95% CI: 1.8-3.6), as well as non-rhabdomyosarcoma soft tissue sarcoma (HR 1.8, 95% CI: 1.3-2.5). The hazard of embryonal rhabdomyosarcoma was markedly increased in children with central nervous system anomalies (HR 7.9, 95% CI: 3.9-15.9), obstructive genitourinary defects (HR 4.6, 95% CI: 2.2-9.7), and limb reduction deformities (HR 3.8, 95% CI: 1.6-9.3).
CONCLUSIONS: Children with non-syndromic congenital anomalies are at increased risk of sarcomas, especially soft tissue sarcomas. Future studies should clarify shared developmental pathways and evaluate implications for sarcoma risk prediction and surveillance.
PROCEDURE: We obtained data on maternal and perinatal characteristics, congenital anomalies, and pediatric sarcoma diagnoses for all live births in nine states. We used Cox proportional hazards regression to estimate the hazard ratio (HR) and 95% confidence interval (CI) of sarcoma (overall and by subtype) among children with non-syndromic congenital anomalies. We considered all non-syndromic anomalies collectively, and when sample size allowed, we also evaluated specific anomaly-sarcoma associations.
RESULTS: We evaluated 21,933,884 children, including 641,770 (2.9%) with major non-syndromic congenital anomalies. Compared to children without a congenital anomaly, children with a non-syndromic anomaly had a two-fold higher hazard for any soft tissue sarcoma (95% CI: 1.7-2.5), including rhabdomyosarcoma (HR 2.2, 95% CI: 1.7-3.0) and embryonal rhabdomyosarcoma (HR 2.5, 95% CI: 1.8-3.6), as well as non-rhabdomyosarcoma soft tissue sarcoma (HR 1.8, 95% CI: 1.3-2.5). The hazard of embryonal rhabdomyosarcoma was markedly increased in children with central nervous system anomalies (HR 7.9, 95% CI: 3.9-15.9), obstructive genitourinary defects (HR 4.6, 95% CI: 2.2-9.7), and limb reduction deformities (HR 3.8, 95% CI: 1.6-9.3).
CONCLUSIONS: Children with non-syndromic congenital anomalies are at increased risk of sarcomas, especially soft tissue sarcomas. Future studies should clarify shared developmental pathways and evaluate implications for sarcoma risk prediction and surveillance.